Last close As at 05/08/2026
NOK2.81
▲ 0.04 (1.44%)
Market capitalisation
NOK918m
Research: Healthcare
Nykode Therapeutics is a clinical-stage biopharmaceutical company with a focus on novel immunotherapies. As part of its Q324 results, it announced a strategic repositioning as a leaner organisation, aiming to streamline its clinical development efforts. With US$124.6m in cash and a runway guided into 2030, Nykode is seeking partnerships for cancer vaccine candidates VB10.16 and VB10.NEO. Both are backed by encouraging early clinical data and have potentially large commercial opportunities, but the company will not be initiating pivotal studies until suitable partners are secured. Nykode’s positioning is underpinned by its proprietary technology, and it aims to advance promising early-stage candidates in a cost-conscious manner, which management believes will be attractive to external parties.
Nykode Therapeutics |
Repositioned to streamline clinical progress
|
Pharma and biotech |
QuickView
9 December 2024 |
Share price graph
Share details
Business description
Bull
Bear
Analyst
|
||||||||||||||||||||||||
Nykode Therapeutics is a clinical-stage biopharmaceutical company with a focus on novel immunotherapies. As part of its Q324 results, it announced a strategic repositioning as a leaner organisation, aiming to streamline its clinical development efforts. With US$124.6m in cash and a runway guided into 2030, Nykode is seeking partnerships for cancer vaccine candidates VB10.16 and VB10.NEO. Both are backed by encouraging early clinical data and have potentially large commercial opportunities, but the company will not be initiating pivotal studies until suitable partners are secured. Nykode’s positioning is underpinned by its proprietary technology, and it aims to advance promising early-stage candidates in a cost-conscious manner, which management believes will be attractive to external parties.
Novel immunotherapy technology platform
Nykode’s immunotherapy platform takes a modular approach to generate novel therapeutics. These comprise three units: a targeting unit that binds to antigen-presenting cells, a dimerization unit and an antigenic unit derived from the disease-causing agent (human papilloma virus (HPV)-16 in the case of VB10.16). The specific targeting of antigens to antigen-presenting cells is essential for inducing efficacious responses. The platform is designed to be versatile and adaptable for creating therapies that induce desired immune responses for a range of indications.
Lead candidates well-positioned for late-stage trials
VB10.16 is an off-the-shelf vaccine targeting HPV-16+ induced malignancies. It has completed its Phase II C-02 trial, showing desirable safety and efficacy in cervical cancer. It is also being tested in the Phase I/IIa C-03 trial for head and neck cancer. The launch of part 2 for C-03 and the next cervical cancer trial (C-05) are reliant on securing a partner. Nykode is reclaiming second asset VB10.NEO from Genentech; the termination notice did not reference clinical data or its platform. It has been tested in two trials (Phase I/II N-01 and Phase Ib N-02) across >10 solid tumour types. Preliminary N-02 data align with and confirm the positive results from N-01.
Cash runway to 2030 while seeking partnerships
Nykode ended Q324 with a cash position of US$124.6m. Following its repositioning as a leaner company, it targets an annualised cost base of c US$20m, providing a runway into 2030. This gives ample operational headroom, allowing management to seek strategic partnerships to advance the progression of its candidates.
|
Consensus estimates
Source: LSEG Data & Analytics |
EDISON QUICKVIEWS ARE NORMALLY ONE-OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.
|
||||||||||||
|
||||||||||||
Research: Industrials
Quadrise has made a significant step towards commercialisation, through which its innovative emulsion fuel technology will contribute to the decarbonisation of the marine sector. The company announced that it has signed a Collaboration and Operational Trial Agreement (the project agreement) with MSC Shipmanagement and Cargill, paving the way for the highly anticipated vessel trials on board the MSC Leandra. The market recognised the significance of this agreement, with Quadrise’s stock price rallying by approximately 50% on the day of the announcement.